(Last updated 17/10/2017; last reviewed 17/10/2017)
Pharmacokinetic (PK) drug-drug interactions between antiretroviral (ARV) drugs and concomitant medications are common, and may lead to increased or decreased drug exposure. In some instances, changes in drug exposure may increase toxicities or affect therapeutic responses. When prescribing or switching one or more drugs in an ARV regimen, clinicians must consider the potential for drug-drug interactions—both those that affect ARVs and those that ARVs affect on other drugs a patient is taking. A thorough review of concomitant medications in consultation with a clinician with expertise in ARV pharmacology can help in designing a regimen that minimizes undesirable interactions. Recommendations for managing a particular drug interaction may differ depending on whether a new ARV is being initiated in a patient on a stable concomitant medication or a new concomitant medication is being initiated in a patient on a stable ARV regimen. The magnitude and significance of interactions are difficult to predict when several drugs with competing metabolic pathways are prescribed concomitantly. When prescribing interacting drugs is necessary, clinicians should be vigilant in monitoring for therapeutic efficacy and/or concentration-related toxicities.
Mechanisms of Pharmacokinetic Interactions
PK interactions may occur during absorption, metabolism, or elimination of the ARV and/or the interacting drugs. The most common mechanisms of interactions are described below and listed for each ARV drug in Table 17.
Pharmacokinetic Interactions Affecting Drug Absorption
The extent of oral absorption of drugs can be affected by the following mechanisms:
- Acid reducing agents, such as proton pump inhibitors, H2 antagonists, or antacids, can reduce the absorption of ARVs that require gastric acidity for optimal absorption (i.e., atazanavir [ATV] and rilpivirine [RPV]).
- Products that contain polyvalent cations, such as aluminum, calcium, magnesium-containing antacids, supplements, or iron products, can bind to integrase inhibitors (INSTI) and reduce absorption of these ARV agents.
- Drugs that induce or inhibit the enzyme cytochrome P450 3A4 (CYP3A4) or efflux transporter p-glycoprotein in the intestines may reduce or promote the absorption of other drugs.
Pharmacokinetic Interactions Affecting Hepatic Metabolism
Two major enzyme systems are most frequently responsible for clinically significant drug interactions.
- The cytochrome P450 enzyme system is responsible for the metabolism of many drugs, including the non-nucleoside reverse transcriptase inhibitors (NNRTI), protease inhibitors (PI), CCR5 antagonist maraviroc (MVC), and the INSTI elvitegravir (EVG). CYP3A4 is the most common enzyme responsible for drug metabolism, though multiple enzymes may be involved in the metabolism of a drug. ARVs and concomitant medications may be inducers, inhibitors, and/or substrates of these enzymes.
- The uridine diphosphate (UDP)-glucuronosyltransferase (UGT) 1A1 enzyme is the primary enzyme responsible for the metabolism of the INSTIs dolutegravir (DTG) and raltegravir (RAL). Drugs that induce or inhibit the UGT enzyme can affect the PKs of these INSTIs.
Pharmacokinetic Enhancers (Boosters)
PK enhancing is a strategy used to increase exposure of an ARV by concomitantly administering a drug that inhibits the enzymes that metabolize the ARV. Currently in clinical practice, two agents are used as PK enhancers: ritonavir (RTV) and cobicistat (COBI). Both of these agents are potent inhibitors of the CYP3A4 enzyme, resulting in higher drug exposures of the coadministered ARV metabolized by this pathway. Importantly, RTV and COBI may have different effects on other CYP or UGT metabolizing enzymes and drug transporters. Complex or unknown mechanisms of PK-based interactions preclude extrapolation of RTV drug interactions to certain COBI interactions, such as interactions with warfarin, phenytoin, voriconazole, oral contraceptives, certain HMG-CoA reductase inhibitors (or statins), and other drugs.
June 2018 - Feedback
Cobicistat (COBI) is only available within Australia as the co-formulated Stribild (EVG/cobi/ TDF/FTC), Genvoya (EVG/cobi/ TAF/FTC), Prezcobix (DRV/cobi) and Evotaz (ATV/cobi) It does not have TGA approval for use as a pharmacological booster with other antiretroviral agents and is not available as a single agent
Other Mechanisms of Pharmacokinetic Interactions
Knowledge of drug transporters is evolving, elucidating additional drug interaction mechanisms. For example, DTG decreases the renal clearance of metformin by inhibiting organic anion transporters in renal tubular cells. Similar transporters aid hepatic, renal, and biliary clearance of drugs and may be susceptible to drug interactions. ARVs and concomitant medications may be inducers, inhibitors, and/or substrates of these drug transporters.
Tables 17-19b provide information on known or suspected drug interactions between ARV agents and commonly prescribed medications based on published PK data or information from product labels. The tables provide general guidance on drugs that should not be coadministered and recommendations for dose modifications or alternative therapy.
Tables 17- Mechanisms Antiretroviral-Associated Drug Interactions
Tables 18 - Drug Interactions between Protease Inhibitors and Other Drugs:
- Table 18 (page 1)
- Table 18 (page 2)
- Table 18 (page 3)
- Table 18 (page 4)
- Table 18 (page 5)
- Table 18 (page 6)
- Table 18 (page 7)
- Table 18 (page 8)
- Table 18 (page 9)
- Table 18 (page 10)
- Table 18 (page 11)
- Table 18 (page 12)
- Table 18 (page 13)
- Table 18 (page 14)
- Table 18 (page 15)
- Table 18 (page 16)
Table 18 (page 17)
Tables 18b - Drug Interactions Between Non-Nucleoside Reverse Transcriptase Inhibitors and Other Drugs:
- Table 18b (page 1)
- Table 18b (page 2)
- Table 18b (page 3)
- Table 18b (page 4)
- Table 18b (page 5)
- Table 18b (page 6)
- Table 18b (page 7)
- Table 18b (page 8)
- Table 18b (page 9)
Tables 18c- Drug Interactions Between Nucleoside Reverse Transcriptase Inhibitors and Other Drugs (Including Antiretroviral Agents):
Tables 18d- Drug Interactions Between Integrase Strand Transfer Inhibitors and Other Drugs:
- Table 18d (page 1)
- Table 18d (page 2)
- Table 18d (page 3)
- Table 18d (page 4)
- Table 18d (page 5)
- Table 18d (page 6)
- Table 18d (page 7)
- Table 18d (page 8)
- Table 18d (page 9)
- Table 18d (page 10)
- Table 18d (page 11)
Tables 18e- Drug Interactions between CCR5 Antagonist (Maraviroc) and Other Drugs (Including Antiretroviral Agents):
Tables 19a- Interactions Between Non-Nucleoside Reverse Transcriptase Inhibitors and Protease Inhibitorsa :
Tables 19b- Interactions between Integrase Strand Transfer Inhibitors and Non-Nucleoside Reverse Transcriptase Inhibitors or Protease Inhibitors: